Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Jun;38(6):1402–1403. doi: 10.1128/aac.38.6.1402

In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.

P M Roblin 1, G Montalban 1, M R Hammerschlag 1
PMCID: PMC188218  PMID: 8092845

Abstract

The in vitro susceptibilities of 12 strains of Chlamydia pneumonia to a new quinolone, OPC-17116; ofloxacin; and sparfloxacin were determined. OPC-17116 was slightly less active than sparfloxacin but more active than ofloxacin, with a MIC for 90% of strains tested and a minimal chlamydiacidal concentration for 90% of strains tested of 0.5 micrograms/ml.

Full text

PDF
1402

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chirgwin K., Roblin P. M., Gelling M., Hammerschlag M. R., Schachter J. Infection with Chlamydia pneumoniae in Brooklyn. J Infect Dis. 1991 Apr;163(4):757–761. doi: 10.1093/infdis/163.4.757. [DOI] [PubMed] [Google Scholar]
  2. Grayston J. T., Campbell L. A., Kuo C. C., Mordhorst C. H., Saikku P., Thom D. H., Wang S. P. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis. 1990 Apr;161(4):618–625. doi: 10.1093/infdis/161.4.618. [DOI] [PubMed] [Google Scholar]
  3. Hammerschlag M. R., Chirgwin K., Roblin P. M., Gelling M., Dumornay W., Mandel L., Smith P., Schachter J. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis. 1992 Jan;14(1):178–182. doi: 10.1093/clinids/14.1.178. [DOI] [PubMed] [Google Scholar]
  4. Hammerschlag M. R., Hyman C. L., Roblin P. M. In vitro activities of five quinolones against Chlamydia pneumoniae. Antimicrob Agents Chemother. 1992 Mar;36(3):682–683. doi: 10.1128/aac.36.3.682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Imada T., Miyazaki S., Nishida M., Yamaguchi K., Goto S. In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116. Antimicrob Agents Chemother. 1992 Mar;36(3):573–579. doi: 10.1128/aac.36.3.573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kenny G. E., Cartwright F. D. Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116. Antimicrob Agents Chemother. 1993 Aug;37(8):1726–1727. doi: 10.1128/aac.37.8.1726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kimura M., Kishimoto T., Niki Y., Soejima R. In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents. Antimicrob Agents Chemother. 1993 Apr;37(4):801–803. doi: 10.1128/aac.37.4.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lipsky B. A., Tack K. J., Kuo C. C., Wang S. P., Grayston J. T. Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections. Am J Med. 1990 Dec;89(6):722–724. doi: 10.1016/0002-9343(90)90212-v. [DOI] [PubMed] [Google Scholar]
  9. Waites K. B., Cassell G. H., Canupp K. C., Fernandes P. B. In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones. Antimicrob Agents Chemother. 1988 Oct;32(10):1500–1502. doi: 10.1128/aac.32.10.1500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Wise R., Andrews J. M., Brenwald N. The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone. J Antimicrob Chemother. 1993 Apr;31(4):497–504. doi: 10.1093/jac/31.4.497. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES